Chronic Lymphocytic Leukemia

Previously Treated

Patients Previously on HEM0028

HEM0048
Phase I/II
Venetoclax + Ibrutinib in Relapsed or Refractory CLL & Small Lymphocytic Leukemia
PI: Coute
Stanford

HEM0048-EXT
Phase 3b PCI-32765 (Ibrutinib) Long-term Extension Study
PI: Coute
Janssen Research & Development

Previously Untreated

Patients Previously on HEM0025, HEMCLL0010-EXT, or HEM0029-EXT

HEM0049
Extended Tx in Subjects Continuing to Benefit from Ibrutinib After Completion of Ibrutinib CT
PI: Coute
Pharmacyscics

KEY
- Pending
- Open for Enrollment
- Optional Path
- Trial Posting
- Extension Study
- Immunotherapy
- Enrollment on Hold

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu